Eton Pharmaceuticals, Inc.

Thank you for standing by. My name is Alex and I will be your conference operator for today. At this time, I would like to welcome everyone to the ATON Pharmaceutical Q2 2025 earnings call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. If you would like to withdraw your question, press star one again. Thank you. I would now like to turn the call over to Mr. David Krempa. Please go ahead.

Thank you, operator. Good afternoon, everyone, and welcome

to EATON second quarter 2025 conference call. This afternoon, we issued a press release that outlines the topics we plan to discuss on today's call. The release is available on our website, eatonpharma.com. Joining me on our call today, we have Sean Brangelson, our CEO, James Gruber, our CFO, and Epek Trinkas, our chief commercial officer. In addition to taking live questions on the call today, we will be answering questions that are emailed to us. Investors can send their questions to investorrelations at eatonpharma.com. Before we begin, I would like to remind everyone that remarks made during today's call may contain forward-looking statements and involves risks and uncertainties that could cause actual results to differ materially from those contained in these forward-looking statements. Please see the forward-looking statements disclaimer in our earnings release and the risk factors in the company's filings with the SEC. Now, I will turn the call over to our CEO, Sean Brangelson.